These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 15522063)
21. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
22. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry]. Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936 [TBL] [Abstract][Full Text] [Related]
31. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535 [TBL] [Abstract][Full Text] [Related]
32. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine. Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671 [TBL] [Abstract][Full Text] [Related]
33. 2-CdA in the treatment of hairy cell leukaemia. Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464 [TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269 [TBL] [Abstract][Full Text] [Related]
35. Hairy cell leukemia: an elusive but treatable disease. Wanko SO; de Castro C Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237 [TBL] [Abstract][Full Text] [Related]
36. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208 [TBL] [Abstract][Full Text] [Related]
37. [Treatment of hairy cell leukemia with cladribine]. Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550 [TBL] [Abstract][Full Text] [Related]
38. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences). Chrobák L; Podzimek K; Zak P; Plísková L; Voglová J Acta Haematol Pol; 1995; 26(2 Suppl 1):56-62. PubMed ID: 7653236 [TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629 [TBL] [Abstract][Full Text] [Related]
40. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Orciuolo E; Buda G; Sordi E; Baraté C; Galimberti S; Ciancia E; Petrini M Leuk Res; 2010 Feb; 34(2):184-9. PubMed ID: 19414190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]